Aegerion Pharmaceuticals Announces Third Quarter 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/31/2026
- Wall Street closes lower as oil prices jump, indexes notch monthly gains
- The Warsh pivot markets didn't expect
- Oil settles up by more than 2.5% as US and Iran resume military attacks
- Energy stocks rally as fresh U.S.-Iran attacks drive oil prices higher
- BofA turns S&P 500 signals from red to yellow: What to buy now
Cowen Cuts Price Target on Aegerion Pharma (AEGR) Following 3Q Results
November 10, 2015 8:35 AM ESTCowen maintained a Market Perform rating on Aegerion Pharmaceuticals (NASDAQ: AEGR), and cut the price target to $15.00 (from $25.00), following the company's 3Q earnings report. Juxtapid sales were $58.8MM, ahead of consensus of $54MM. Myalept revenue of $8.5MM was ahead of consensus of... More
Aegerion Pharma (AEGR) Tops Q3 EPS by 8c
November 9, 2015 4:22 PM ESTAegerion Pharma (NASDAQ: AEGR) reported Q3 EPS of ($0.34), $0.08 better than the analyst estimate of ($0.42). Revenue for the quarter came in at $67.3 million versus the consensus estimate of $59.72 million.
Aegerion Pharma sees FY2015 revenue of $230-245 million, versus the consensus of $239.1 million.
For... More
